Delving into the Latest Updates on POC-101 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

POC101

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Shanghai Changcheng Medical Technology Co., Ltd.

Active Organization

Shanghai Changcheng Medical Technology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的: 评估POC101在晚期实体瘤患者中的安全性和耐受性；观察POC101的剂量限制性毒性（DLT），确定POC101在晚期实体瘤患者中的最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）。次要目的：评估POC101在晚期实体瘤患者中的药代动力学（PK）特征、食物影响和代谢产物鉴定；评估POC101在晚期实体瘤患者中的初步抗肿瘤活性和肿瘤生物标志物（如适用）的变化情况。

[Translation]

Primary objectives: Evaluate the safety and tolerability of POC101 in patients with advanced solid tumors; Observe the dose-limiting toxicity (DLT) of POC101 and determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of POC101 in patients with advanced solid tumors. Secondary objectives: Evaluate the pharmacokinetic (PK) characteristics, food effects, and metabolite identification of POC101 in patients with advanced solid tumors; Evaluate the preliminary anti-tumor activity of POC101 in patients with advanced solid tumors and changes in tumor biomarkers (if applicable).

Start Date27 Mar 2025

Sponsor / Collaborator

Shanghai Changcheng Medical Technology Co., Ltd.

100 Clinical Results associated with POC-101

Login to view more data

100 Translational Medicine associated with POC-101

Login to view more data

100 Patents (Medical) associated with POC-101

Login to view more data

100 Deals associated with POC-101

Login to view more data